disease (CVD) and diabetes, especially type 2, are closely intertwined and growing health threats in the US and many other regions of the world.
The ACCORD Trial
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was a double 2x2 factorially designed trial. It randomized 10,251 patients with type 2 diabetes (62% male, mean age 62 years) to intensive (target HbA 1c <6%) versus standard (target HbA 1c range 7.0-7.9%) treatment for a planned follow-up of 5.5 years. 19 All US Food and Drug Administration (FDA)-approved drugs were used in both treatment groups. The primary outcome was a composite of CVD death and nonfatal MI and stroke. The intensive glycemic treatment group experienced a 22% increase in total mortality (p=0.04) and a 35% increase in CVD mortality (p=0.02) after 3.5 years. 20 This prompted a transfer of this patient group to standard therapy for the remainder of the trial. The increased mortality with intensive treatment was not associated with severe hypoglycemic episodes or lower HbA 1c , but with a failure to reduce HbA 1c promptly. Up to this point, the median HbA 1c was 6.4% in the intensive and 7.5% in the standard group. The intensive treatment group had a 24% reduction in non-fatal MI (p=0.004). 20 Moreover, in subgroup analyses, patients with no previous CVD events and patients with HbA 1c ≤8.0% at baseline had reductions in the primary outcome compared with those with the opposite characteristics. Intensive therapy was again associated with three times the number of severe hypoglycemic episodes as standard therapy. 20 The ADVANCE Trial Intensive treatment led to a non-significant reduction of 6% (p=0.32).
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Severe hypoglycemia was more common in the intensive group (2.7 versus 1.5%; p<0.001).
Meta-analysis of Trials
A recent meta-analysis 22 
Thiazolidinedione Drugs
The two currently marketed agents in this class are rosiglitazone (Avandia) and pioglitazone (Actos). There is some debate about their relative effectiveness and safety with regard to CVD.
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Pioglitazone PROACTIVE included 5,238 patients with type 2 diabetes (mean age 62 years, 67% male), all with prior evidence of CVD. Patients were randomly assigned to titrated doses of pioglitazone or placebo in addition to their usual glycemic therapy. They were followed for three years. p<0.001). There was no effect on total mortality. No difference emerged in the primary or principal secondary outcomes over a five-year follow-up period between the insulin-sensitization and insulin-provision groups or between the revascularization and medical therapy control groups. 35 In the CABG stratum, however, there was a 12% reduction in the composite of death, MI, or stroke compared with medical therapy (p=0.01). This was largely accounted for by a significant 49% reduction in non-fatal MI. 35 Strikingly, the composite outcome was reduced by 42% (p=0.002) in the insulin-sensitization group of those randomized to CABG, but only 10% in the insulin-provision group (p=0.58). Within the CABG stratum, the composite outcome was 18.7%
for insulin sensitization versus 26% for insulin provision (p=0.066). Severe hypoglycemia was 36% less frequent with insulin-sensitization than with insulin-provision treatment (p=0.003), and was largely accounted for by the addition of insulin to improve HbA 1c . 35 The mechanism for the unique beneficial interaction between CABG and insulin sensitization remains to be elucidated, but this interaction suggests a pathogenetic relationship between metabolic and anatomical abnormalities in diabetic CAD.
Meta-analysis Pioglitazone
Nineteen trials involving 16,390 patients with type 2 diabetes followed for between four months and 3.5 years were analyzed. • no access to individual patient data;
• use of non-adjudicated CVD events;
• a small number of events;
• the inclusion of trials with zero events in one of the two arms; and
• a heterogeneous population.
A second meta-analysis included only four major trials comprising 14,291 diabetic and pre-diabetic patients followed for at least one year. 39 • The direct association of HbA 1c with CVD outcomes in observational studies may be just that: hyperglycemia may be only a marker for the real causative factor(s) that are not proportionately reduced when blood glucose is actively lowered.
• The effect of hyperglycemia reduction on CVD risk may be small compared with the effect on microvascular complications and therefore beneath the power of feasible studies to detect.
• Blood glucose may need to be kept down (HbA 1c <7.0%) from early on in type 2 diabetes and for many years to reap a CVD benefit. The UKPDS results point to such a conclusion. If this is so, intensive treatment begun in elderly patients at greater CVD risk but with shorter life expectancies may be both ineffectual and, as per the ACCORD results, dangerous.
• The actual event rates in the control groups of recent major randomized clinical trials have turned out to be lower than projected, probably because of better management of other even more powerful risk factors, limiting study power.
In this context it may be asked whether any additional CVD benefit will be attainable by lowering blood glucose, given the effectiveness of reducing low-density lipoprotein (LDL) cholesterol and systolic blood pressure and the possible benefit of increasing HDL cholesterol and reducing triglycerides. 42 Patients with diabetes respond as well as those without to statin therapy in randomized clinical trials. 42, 43 In a meta-analysis of statin therapy involving 90,000 patients, 21% of whom had diabetes, each mmol/l reduction (39mg/dl) in LDL cholesterol was associated with a 23% reduction in coronary death or MI and a similar reduction in need for coronary revascularization. Statin therapy was also associated with a 17% reduction in fatal or non-fatal stroke. 43 Moreover, a greater reduction in events can be achieved using a maximum statin dose that lowers LDL cholesterol to 77mg/dl. 44 Reducing systolic blood pressure-and with it diastolic blood pressure-also decreases the risk of CVD events, especially strokes, in patients with and without diabetes. 41 In a large meta-analysis involving 159,000 patients (21% with diabetes), more compared with less intensive blood-pressure-lowering significantly reduced stroke by 36%, major CVD events by 25%, and total mortality by 27%, but not coronary heart disease, in patients with diabetes. 45 Similar benefits have been individually noted in the UKPDS, 46 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 47 and ADVANCE trials. Of the two TZDs, the bulk of the evidence gives the advantage to pioglitazone. In oral presentations at American Diabetes Association meetings, neither ACCORD nor BARI 2D reported an association between rosiglitazone-used much more often in each study than pioglitazone-and adverse CVD outcomes. Even when reported fully, however, these will be secondary epidemiological analyses with lesser weight in assessing safety. A consensus algorithm for treating type 2 diabetes relegates TZDs to a second tier and no longer recommends rosiglitazone. 49 The survival of the latter in the therapeutic armamentarium, which is debatable, 50-52 may depend on offering financial advantages that translate into greater cost-effectiveness.
The results of the BARI 2D trial showed a trend toward reduced CVD outcomes with a regimen that was based on insulin sensitization with metformin and/or TZDs. Most intriguing was the observation that CABG was superior to medical therapy alone, particularly in reducing the incidence of MI in the insulin-sensitization glycemic arm but not in the insulin-provision glycemic arm. These results indicate that patients about to undergo CABG whose HbA 1c is >7.0% should have metformin and/or a TZD added to their glycemic management, rather than a beta-cell stimulant or an increased dose of insulin.
Conclusion
There is still the need for more definitive randomized clinical trial evidence to determine whether lowering blood glucose reduces CVD late in type 2 diabetes and whether using a particular therapeutic approach to glycemic control provides an advantage. 
